CRISPR-engineered T cells in patients with refractory cancer.
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
28 02 2020
28 02 2020
Historique:
received:
03
01
2020
accepted:
28
01
2020
pubmed:
8
2
2020
medline:
6
5
2020
entrez:
8
2
2020
Statut:
ppublish
Résumé
CRISPR-Cas9 gene editing provides a powerful tool to enhance the natural ability of human T cells to fight cancer. We report a first-in-human phase 1 clinical trial to test the safety and feasibility of multiplex CRISPR-Cas9 editing to engineer T cells in three patients with refractory cancer. Two genes encoding the endogenous T cell receptor (TCR) chains, TCRα (
Identifiants
pubmed: 32029687
pii: science.aba7365
doi: 10.1126/science.aba7365
pii:
doi:
Substances chimiques
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Receptors, Antigen, T-Cell, alpha-beta
0
CRISPR-Associated Protein 9
EC 3.1.-
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : R01 CA120409
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG066100
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.